title: Gamma-interferon and tumor necrosis factor production after bone marrow transplantation is augmented by exposure to marrow fibroblasts infected with cytomegalovirus.
abstract: After bone marrow transplantation (BMT), mortality from viral infections such as cytomegalovirus (CMV) remains high. Gamma-Interferon (gamma IFN) and tumor necrosis factor (TNF) are produced constitutively after BMT and have anti-viral properties. To study the effects of these cytokines on CMV interaction with host cells, we have used patient marrow fibroblasts since marrow stroma is a target for CMV infection correlating with myelosuppression in vivo. Both gamma IFN and TNF are constitutively produced by recipient CD3+ and CD16+ lymphocytes, but not by their marrow fibroblasts. Secretion by peripheral blood mononuclear cells is increased if they are cultured with host fibroblasts infected with CMV in vitro and the levels of gamma IFN and TNF produced are within the range that protects fresh fibroblasts from CMV infection. Constitutive secretion of cytokines by lymphocytes declines by 8 weeks after BMT, a time when the risk of CMV disease increases sharply. The in vitro phenomenon that we have described needs to be evaluated in correlative studies on individual BMT recipients to determine whether such a cytokine-mediated defense mechanism against CMV may operate in vivo.
authors.affiliation: Department of Haematology, Royal Free Hospital, Hampstead, London.
authors.forename: A S
authors.initials: AS
authors.lastname: Duncombe
authors.forename: A
authors.initials: A
authors.lastname: Meager
authors.forename: H G
authors.initials: HG
authors.lastname: Prentice
authors.forename: J E
authors.initials: JE
authors.lastname: Grundy
authors.forename: H E
authors.initials: HE
authors.lastname: Heslop
authors.forename: A V
authors.initials: AV
authors.lastname: Hoffbrand
authors.forename: M K
authors.initials: MK
authors.lastname: Brenner
mesh_terms: D015703:Antigens, CD / Q000032:analysis; D001853:Bone Marrow / Q000276:immunology / Q000502:physiology; D016026:Bone Marrow Transplantation / Q000276:immunology / Q000502:physiology*; D002478:Cells, Cultured; D003587:Cytomegalovirus / Q000187:drug effects / Q000235:genetics*; D005347:Fibroblasts / Q000166:cytology / Q000276:immunology; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis* / Q000494:pharmacology; D007938:Leukemia / Q000601:surgery; D008214:Lymphocytes / Q000276:immunology; D011994:Recombinant Proteins / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis* / Q000494:pharmacology; D014746:Vimentin / Q000032:analysis
chemical_list: D015703:Antigens, CD; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D014746:Vimentin; D007371:Interferon-gamma